Dermatomyositis and myelodysplastic syndrome with myelofibrosis responding to methotrexate therapy.
Dermatomyositis (DM) has not yet been reported as a complication of myelodysplastic syndrome (MDS). A 50-year-old man was diagnosed as having MDS because of the presence of anemia, the appearance of immature cells in peripheral blood, and the abnormal cellular morphology. A few months later, high fever, myalgia and erythema developed. Although DM symptoms were resistant to high-dose corticosteroid administration, methotrexate (MTX) therapy improved not only the symptoms of DM but also hematologic findings related to MDS. This indicates that immunosuppressive therapy including MTX administration can be useful for patients with MDS with autoimmune symptoms.
Division of Clinical Pathology and Immunology, Kobe University Graduate School of Medicine, Kobe, Japan.
Goh
G
Tsuji
Soichiro
S
Maekawa
Katsuyasu
K
Saigo
Yumiko
Y
Nobuhara
Tomoko
T
Nakamura
Seiji
S
Kawano
Masahiro
M
Koshiba
Shunichiro
S
Asahara
Tadanobu
T
Chinzei
Shunichi
S
Kumagai
D001773:Blood Cells / Q000473:pathology; D001854:Bone Marrow Cells / Q000473:pathology; D003882:Dermatomyositis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D055728:Primary Myelofibrosis / Q000209:etiology / Q000473:pathology; D016896:Treatment Outcome
D008727:Methotrexate